Literature DB >> 15225794

Rescue of the phenotype of CYP27B1 (1alpha-hydroxylase)-deficient mice.

Olivier Dardenne1, Josée Prud'homme, Francis H Glorieux, René St-Arnaud.   

Abstract

The treatment of choice for pseudo Vitamin D deficiency rickets (PDDR), caused by mutations in the 25-hydroxyvitamin D-1alpha-hydroxylase (CYP27B1; 1alpha-OHase) gene, is replacement therapy with 1,25(OH)(2)D(3). We have previously engineered an animal model of PDDR by targeted inactivation of the 1alpha-OHase gene in mice (Endocrinology 142 (2001) 3135). Replacement therapy was performed in this model, and compared to feeding with a high calcium diet containing 2% calcium, 1.25% phosphorus, 20% lactose (rescue diet). Blood biochemistry analysis revealed that both rescue treatments corrected the hypocalcemia and secondary hyperparathyroidism. Bone histology and histomorphometry confirmed that the rickets and osteomalacia were cured by both rescue protocols. However, despite the restoration of normocalcemia, the rescue diet did not entirely correct bone growth as femur size remained significantly smaller than control in 1alpha-OHase(-/-) mice fed the rescue diet. These results demonstrate that correction of the abnormal mineral ion homeostasis by feeding with a high calcium rescue diet is effective to rescue the PDDR phenotype of 1alpha-OHase mutant mice. This treatment, however, does not appear as effective as 1,25(OH)(2)D(3) replacement therapy since bone growth remained impaired.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15225794     DOI: 10.1016/j.jsbmb.2004.03.026

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  7 in total

Review 1.  The biology and pathology of vitamin D control in bone.

Authors:  Taison D Bell; Marie B Demay; Sherri-Ann M Burnett-Bowie
Journal:  J Cell Biochem       Date:  2010-09-01       Impact factor: 4.429

2.  The receptor-dependent actions of 1,25-dihydroxyvitamin D are required for normal growth plate maturation in NPt2a knockout mice.

Authors:  Susanne U Miedlich; Eric D Zhu; Yves Sabbagh; Marie B Demay
Journal:  Endocrinology       Date:  2010-08-04       Impact factor: 4.736

3.  Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals.

Authors:  Despina Sitara; Mohammed S Razzaque; René St-Arnaud; Wei Huang; Takashi Taguchi; Reinhold G Erben; Beate Lanske
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

4.  Vitamin D Deficiency During Development Permanently Alters Liver Cell Composition and Function.

Authors:  Kassidy Lundy; John F Greally; Grace Essilfie-Bondzie; Josephine B Olivier; Reanna Doña-Termine; John M Greally; Masako Suzuki
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-12       Impact factor: 6.055

5.  Analysis of CYP27B1, encoding 25-hydroxyvitamin D-1alpha-hydroxylase, as a candidate tumor suppressor gene in primary and severe secondary/tertiary hyperparathyroidism.

Authors:  Kelly Lauter; Andrew Arnold
Journal:  J Bone Miner Res       Date:  2009-01       Impact factor: 6.741

Review 6.  Phosphate homeostasis and its role in bone health.

Authors:  Maria Goretti Penido; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2012-05-03       Impact factor: 3.714

Review 7.  Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation.

Authors:  Jordi Bover; Mario Cozzolino
Journal:  Kidney Int Suppl (2011)       Date:  2011-09
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.